Modus Therapeutics participates in Småbolagspodden

Stockholm, Wednesday, October 27, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company participates in the latest episode of Småbolagspodden.

Modus’ CEO John Öhd and CFO Claes Lindblad are interviewed by Småbolagspodden's Jonathan Furelid. Listen in to the discussions on sepsis, one of the most prevalent death causes globally and Modus' development of sevuparin for sepsis and other patients with high unmet medical needs, as well as a further look into what the future plans for Modus look like.

To listen to the episode via Småbolagspodden, click here

To listen to the episode via Spotify, click here

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: [email protected]

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: [email protected]

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.